

Cover Story
NCI Director's Report
By Matthew Bin Han Ong
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- In the Headlines: Is oncology ready to move away from animal testing?
- Imaging’s ride to the bottom in clinical trials—and why it matters now
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology - The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic